Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

Haematologica

Volumn 95, Issue 5, 2010, Pages 738-744

  Erben, Philipp ^a   Gosenca, Darko ^a   Müller, Martin C ^a   Reinhard, Jelena ^a   Score, Joannah ^b   del Valle, Francesco ^c   Walz, Christoph ^a   Mix, Jürgen ^a   Metzgeroth, Georgia ^a   Ernst, Thomas ^b,d   Haferlach, Claudia ^e   Cross, Nicholas C P ^b   Hochhaus, Andreas ^d   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c KLINIKUM OLDENBURG   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Myeloproliferative neoplasm; Pdgfra; Pdgfrb; Rq pcr

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EOSINOPHILIA; FEMALE; FUSION GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HYPEREOSINOPHILIC SYNDROME; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; BASE SEQUENCE; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; EOSINOPHILIA; FEMALE; GENETIC TESTING; HL-60 CELLS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 77952314695     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016345     Document Type: Article

References (39)

1. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med. 2009;13(2):215-37.
2. Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008;22(7): 1320-34.
3. Reiter A, Walz C, Cross NC. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets. 2007;8(2):205-16.
4. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-14.
6. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77(2):307-16.
7. Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173-9.
8. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood. 2007;109(1):61-4.
9. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183-8.
10. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, et al. Lowdose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109(11):4635-40.
11. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347(7):481-7.
12. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008;143(5):707-15.
13. Score J, Walz C, Jovanovic JV, Jones AV, Waghorn K, Hidalgo-Curtis C, et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions. Leukemia. 2009;23(2):332-9.
14. Kulkarni S, Heath C, Parker S, Chase A, Iqbal S, Pocock CF, et al. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABLnegative myeloproliferative disorders with a t(5;10)(q33;q21). Cancer Res. 2000;60(13): 3592-8.
15. Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, et al. The molecular anatomy of the FIP1L1-PDGFRA fusion gene. Leukemia. 2009;23(2):271-8.
16. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11(12):1391-7.
17. Curtis CE, Grand FH, Musto P, Clark A, Murphy J, Perla G, et al. Two novel imatinib- responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol. 2007;138(1):77-81.
18. Walz C, Curtis C, Schnittger S, Schultheis B, Metzgeroth G, Schoch C, et al. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2- PDGFRA fusion gene. Genes Chromosomes Cancer. 2006;45(10):950-6.
19. Score J, Curtis C, Waghorn K, Stalder M, Jotterand M, Grand FH, et al. Identification of a novel imatinib responsive KIF5BPDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 2006; 20(5):827-32.
20. Schwaller J, Anastasiadou E, Cain D, Kutok J, Wojiski S, Williams IR, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 2001;97(12):3910-8.
21. Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V, et al. Characterization of three new imatinibresponsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica. 2007; 92(2):163-9.
22. Walz C, Haferlach C, Hanel A, Metzgeroth G, Erben P, Gosenca D, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer 2008;48:179-83.
23. Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 1994;8(19):186-9.
24. Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer. 1999;26(3):192-202.
25. Arber DA, Chang KL, Lyda MH, Bedell V, Spielberger R, Slovak ML. Detection of NPM/MLF1 fusion in t(3;5)-positive acute myeloid leukemia and myelodysplasia. Human Pathology. 2003;34(8):809-13.
26. Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003;17(12):2392-400.
27. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013-34.
28. Muller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22(1):96-102.
29. Nagase T, Seki N, Tanaka A, Ishikawa K-i, Nomura N.; Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1;. DNA Res.; 1995;2(4):167-74.
30. Bell M, Schreiner S, Damianov A, Reddy R, Bindereif A. p110, a novel human U6 snRNP protein and U4/U6 snRNP recycling factor. Embo J. 2002;21(11):2724-35.
31. Sasatomi T, Suefuji Y, Matsunaga K, Yamana H, Miyagi Y, Araki Y, et al. Expression of tumor rejection antigens in colorectal carcinomas. Cancer. 2002;94(6): 1636-41.
32. Suefuji Y, Sasatomi T, Shichijo S, Nakagawa S, Deguchi H, Koga T, et al. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients. Br J Cancer. 2001;84(7):915-9.
33. Komohara Y, Harada M, Arima Y, Suekane S, Noguchi M, Yamada A, et al. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma. Int J Oncol. 2006;29(6):1555-60.
34. Medenbach J, Schreiner S, Liu S, Luhrmann R, Bindereif A. Human U4/U6 snRNP recycling factor p110: mutational analysis reveals the function of the tetratricopeptide repeat domain in recycling. Mol Cell Biol. 2004;24(17):7392-401.
35. Hidalgo-Curtis C, Chase A, Drachenberg M, Roberts MW, Finkelstein JZ, Mould S, et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer. 2008;47(5):379-85.
36. Chen J, Williams IR, Kutok JL, Duclos N, Anastasiadou E, Masters SC, et al. Positive and negative regulatory roles of the WWlike domain in TEL-PDGFâR transformation. Blood. 2004;104(2):535-42.
37. Irusta PM, Luo Y, Bakht O, Lai C-C, Smith SO, DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem. 2002;277(41):38627-34.
38. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood. 2002;99(5):1776-84.
39. Murati A, Adelaide J, Gelsi-Boyer V, Etienne A, Remy V, Fezoui H, et al. t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera. Leukemia. 2006;20(6):1175-8.